MedPath

Acute Response to Cigarette and E-cigarette Smoking Assesed in Exhaled Breath Condensate in Healthy Smokers of Traditional and E-cigarettes

Conditions
E-cigarettes
Registration Number
NCT03153228
Lead Sponsor
Medical University of Warsaw
Brief Summary

Electronical cigarettes, also known as "e-cigarettes" are a new phenomenon, which steadily wins more aprobation among smokers. However, there exists no much data concerning the effects of acute exposure to electronic cigarettes vapour on the respiratory system.

The aim of the present study is to evaluate and compare the acute response to electronic and traditional cigarettes in healthy smokers.

Detailed Description

The aim of the study is:

* to evaluate the acute response to traditional cigarettes on the respiratory system

* to evaluate the acute response to electronic cigarettes on the respiratory system

* to assess the relationship between the type of smoked cigarettes (traditional vs. electronic) and concentration of markers of airway inflammation released in healthy smokers

Material and methods:

* 29 healthy smokers of traditional cigarettes

* 29 healthy smokers of electronic cigarettes

* 29 healthy, nonsmoking volunteers

After 8 hours of smoking abstinence:

* the spirometry test

* the first collection of the exhaled breath condensate (EBC I)

* smoking a traditional / electronic cigarette

* the second collection of the exhaled breath condensate (EBC II) - one hour after smoking

* the third collection of the exhaled breath condensate (EBC III) - six hours after smoking

* the measurement of biomarkers of oxidative stress in the EBC (isoprostane-8, malondialdehyde MDA, IL-8) and pH of the EBC

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
87
Inclusion Criteria
  • healthy smokers of traditional cigarettes - min. 1 packyear
  • healthy smokers of e-cigarettes - min. 1 year of smoking history
  • control group - healthy nonsmoking volunteers without any history of lung disease
Exclusion Criteria
  • age below 18 years
  • inhaled corticosteroid therapy at least 6 weeks prior to study enrollment
  • any co-morbidities
  • respiratory infections at least 6 weeks prior to study enrollment

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Inflammatory markers in exhaled breath condensateApproximately 1-2 months after completion of study procedures in all patients

Inflammatory markers in exhaled breath condensate in healthy subjects, smokers of traditional cigarettes and e-cigarette smokers

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Medical University of Warsaw, Banacha Hospital

🇵🇱

Warsaw, Poland

© Copyright 2025. All Rights Reserved by MedPath